• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Wright Medical slips on Q3 results, despite higher earnings outlook

Wright Medical slips on Q3 results, despite higher earnings outlook

November 6, 2012 By MassDevice staff

Wright Medical

Wright Medical (NSDQ:WMGI) beat Wall Street’s earnings expectations, narrowed its 3rd-quarter losses by ⅔ and boosted its outlook for 2012, but missed sales numbers prompted investors to shave more than 3% from its share price today.

The Arlington, Tenn.-based joint replacement maker posted losses of $5.3 million, or 14¢ per share, on sales of $110.4 million during the 3 months ended Sept. 30, narrowing losses by 66.7% despite a 6.6% top-line slide.

Excluding 1-time items, adjusted earnings per share were 1¢, well ahead of analysts’ -5¢ consensus. But Wall Street boffins were also looking for about $1.6 million more in sales. The news erased and then some the 2.6% gain WMGI shares posted yesterday, ahead of Wright’s post-market earnings announcement. WMGI shares were trading at $20.29 apiece as of about 3:40 p.m., down 2.9% on the day and half a percent under its $29.37 closing mark Nov. 2.

President & CEO Robert Palmisano said Wright is making progress on its plan to reorganize the business, a process embarked on after a damaging federal kickbacks beef that led to the ouster of former CEO Gary Henley and chief technology officer Frank Bono. Wright brought Palmisano in to clear up the mess in September 2011.

"We continued to make excellent progress on implementing our transformational changes in our business during the 3rd quarter. In addition to our 3rd consecutive quarter of accelerating global foot and ankle growth, we continue to generate strong cash flow. We also completed the conversion of a major portion of our foot and ankle distributor territories to direct sales representation. With this conversion now complete, coupled with the favorable response to our recent new product launches and increased medical education programs, we believe we are well positioned to exit the year at well above market growth rates and improve sales productivity in our foot and ankle business," Palmisano said in prepared remarks.

Analyst Richard Newitter said the company does seem to be making progress in its recovery, citing the growth in foot & ankle implant sales and the increased free cash flow.

"We continue to believe WMGI is moving onto a path of improved performance/execution. But there’s still work ahead, and to us the current valuation already seems to reflect better-than-expected turnaround execution – at least to some degree. Nearer-term we think multiple expansion from current levels could be limited without additional signs that WMGI’s sales growth, operating margin and cash flow improvement initiatives are all tracking more meaningfully ahead of plan," Newitter wrote in a note to investors today, maintaining the investment bank’s "market perform" rating and raising its price target from $20 to $23.

Wright reaffirmed its 2012 sales guidance of $476 million to $485 million and boosted its adjusted EPS outlook from 32¢-36¢ to 34¢-40¢.

Newitter added that the Oct. 8 expiration of a deferred prosecution agreement over the kickbacks beef – which was extended by a year in October 2012 – "removes a legal overhang."

But another overhang remains – a federal probe into its Profemur metal-on-metal hip implant and a raft of personal injury lawsuits over the device. Wright, estimating its liability for the older titanium Profemur model at $23 million to $37 million, set aside $23 million to cover those costs over the next 4 years, according to a regulatory filing.

Wright’s insurer hasn’t said whether it will cover the Profemur claims, according to the filing, but said its carrier could decide to cover those claims under the policy inked the year the 1st claim was filed. That was the call for personal injury cases filed over another of Wright’s metal-on-metal hip implants called Conserve. Wright recorded an estimated $3.8 million insurance recovery for Profemur cases, against an estimated $7.1 million in open claims. The new insurance policy specifically excludes coverage of lawsuits filed over the titanium Profemur device, according to the filing.

WMGI shares closed down 3.4% at $20.20 today.

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2012, Q3, wrightmedical

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy